HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit an electronic Letter to the Editor about this paper Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via ISI Web of Science (5) Citing Articles via Google Scholar Google Scholar Articles by Kinter, M. Search for Related Content PubMed PubMed Citation Articles by Kinter, M. Related Collections Molecular Diagnostics and Genetics

Toward Broader Inclusion of Liquid Chromatography-Mass Spectrometry in the Clinical Laboratory

¹ Department of Cell Biology, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH
² Department of Physiology and Biophysics, Case Western Reserve University School of Medicine, Cleveland, OH
³ Department of Chemistry, Cleveland State University, Cleveland, OH

The first 300 words of the full text of this article appear below.

Mass spectrometry is widely appreciated as a powerful analytical method, characterized by high sensitivity and high information content, that can be used for both the qualitative and quantitative analysis of nearly all types of molecules. In light of this power, I would propose that mass spectrometry is ready for a substantially larger role in routine clinical analyses.

In this issue of Clinical Chemistry, Muddiman and coworkers from the Mayo Clinic present reports in which two levels of mass spectrometry experiments are used to detect and characterize transthyretin variants by accurately measuring the molecular mass of the intact protein isolated from human serum (1)(2). As described by the authors, transthyretin variants can form amyloid in tissues that may ultimately damage those tissues. Currently, diagnosis is generally made after symptoms appear by detecting the amyloid in biopsies of the affected tissue.

The report by Nepomuceno et al. (1) uses a sophisticated dual-source electrospray ionization-Fourier transform ion cyclotron resonance (FT-ICR) mass spectrometry system to make the transthyretin molecular mass measurement and detect the variant protein. These FT-ICR instruments are the current pinnacle of mass spectrometry performance, vastly exceeding any other instrument type in all relevant issues of merit, including resolution, sensitivity, and mass range. The power of the FT-ICR instrument, and the unique dual-ion source designed and developed by this group (3), is used to carry out an experiment in which the molecular mass of the intact transthyretin protein is measured with an extraordinary mass accuracy of <3 parts per million (i.e., mass accuracy to within 0.05 Da for the 13 761-Da protein). The result of this mass accuracy is illustrated by both the proper detection of several known transthyretin variants and the detection and characterization of a novel double-mutant based on a 2-Da . . . [Full Text of this Article]